市場調查報告書
商品編碼
1309835
肽治療藥物市場 - 按類型(品牌、非專利)、按應用(代謝、癌症、心血管、胃腸道)、按給藥途徑(腸外、口服)、按銷售管道(醫院、零售) - 2023 年至 2032 年全球預測Peptide Therapeutics Market - By Type (Branded, Generic), By Application (Metabolic, Cancer, Cardiovascular, Gastrointestinal), By Route of Administration (Parenteral, Oral), By Distribution Channel (Hospital, Retail)- Global Forecast 2023 to 2032 |
全球多肽治療藥物市場將在2023-2032 年間呈現指數級成長。
由於糖尿病、癌症和心血管疾病等慢性疾病的負擔日益加重,人們對個性化和靶向治療方案的需求不斷增加,這將在未來十年內刺激該行業的收入流。據世界衛生組織統計,全球約有4.22 億人患有糖尿病,每年有150 萬人因此喪生。
多肽療法具有高特異性、低毒性和良好的生物相容性等優勢,是藥物開發的理想選擇。多肽合成技術和給藥系統的進步提高了多肽藥物的穩定性、生物利用度和半衰期,進一步推動了多肽藥物的應用。此外,隨著學術機構與製藥公司之間合作的不斷增加,研發活動也在持續進行,這將促進新型多肽療法的發現,推動市場成長。
多肽療法的總體市場佔有率根據類型、應用、給藥途徑、銷售管道和地區進行分類。
就類型而言,到2032 年,非專利肽療法行業將取得顯著成長。多肽原研藥的專利到期為非專利藥開闢了市場,提供了具有成本效益的替代品。慢性疾病負擔日益加重,需要經濟實惠的治療方案,這進一步刺激了對非專利多肽療法的需求。此外,促進使用學名藥的監管措施也鼓勵了全球醫療系統採用學名藥,這將有助於在未來幾年擴大細分市場的收益。
在應用方面,癌症領域的多肽療法市場規模將在2023-2032 年間大幅成長。由於多肽具有靶向和個性化治療的潛力,癌症應用領域對多肽治療劑的需求不斷增加。多肽可專門針對癌細胞,同時保護健康細胞,減少副作用。此外,基於多肽的免疫療法(如免疫檢查點抑製劑)在增強機體對癌細胞的免疫反應方面也顯示出良好的效果。
根據給藥途徑,到2032 年,口服部分將佔據多肽療法行業收入的顯著佔有率。口服給藥是一種非侵入性的給藥方式,對患者來說更方便,能提高依從性和治療的堅持性。製劑技術的進步,如多肽穩定劑和酶抑製劑的使用,提高了多肽藥物的口服生物利用度和穩定性。此外,與注射或輸液等其他途徑相比,口服給藥具有節約成本的潛力,從而進一步促進了該細分市場的發展。
就地區而言,亞太地區多肽治療市場在2023 年至2032 年期間將呈現可觀的成長率。癌症、糖尿病和心血管疾病等慢性疾病的發病率不斷上升,對有效的治療方案產生了巨大需求。醫療保健支出的增加、中產階級人口的擴大以及醫療保健基礎設施的改善進一步促進了需求的成長。此外,中國、日本和韓國等國研發能力的提高促進了創新,基於多肽的療法的開發將推動該地區市場的成長。
Global Peptide Therapeutics Market will exhibit exponential growth over 2023- 2032.
Increasing demand for personalized and targeted treatment options pushed by the growing burden of chronic diseases such as diabetes, cancer, and cardiovascular disorders will stimulate industry revenue streams over the next ten years. According to WHO, diabetes affects around 422 million people worldwide and claims the lives of 1.5 million people each year.
Peptide therapeutics offer advantages like high specificity, low toxicity, and excellent biocompatibility, making them an attractive choice for drug development. Advancements in peptide synthesis technologies and drug delivery systems have improved the stability, bioavailability, and half-life of peptide drugs, further propelling their adoption. Moreover, ongoing R&D activities, in line with increasing collaborations between academic institutions and pharmaceutical companies, will fuel the discovery of novel peptide-based therapies, driving market growth.
The overall peptide therapeutics market share is categorized based on type, application, route of administration, distribution channel, and region.
Regarding the type, the generic peptide therapeutics industry will register significant gains through 2032. The expiration of patents for original peptide drugs has opened the market for generic versions, offering cost-effective alternatives. The increasing burden of chronic diseases has created a need for affordable treatment options, further stimulating the demand for generic peptide therapeutics. Besides, regulatory initiatives promoting the use of generic drugs have encouraged their adoption in healthcare systems worldwide, which will help augment segment gains over the coming years.
With respect to application, the peptide therapeutics market size from the cancer segment will grow substantially over 2023-2032. The demand for peptide therapeutics in cancer applications is increasing due to their potential for targeted and personalized treatment. Peptides can specifically target cancer cells while sparing healthy cells, reducing side effects. Additionally, peptide-based immunotherapies, such as immune checkpoint inhibitors, have shown promising results in boosting the body's immune response against cancer cells.
Based on the route of administration, the oral segment could amass a notable share of the peptide therapeutics industry revenue by 2032. Oral delivery is non-invasive and more convenient for patients, improving compliance and treatment adherence. Advances in formulation technologies, such as the use of peptide stabilizers and enzyme inhibitors, have improved the oral bioavailability and stability of peptide drugs. This apart, oral delivery offers potential cost savings compared to other routes, such as injections or infusions, further contributing to segment gains.
Regionally, the Asia Pacific peptide therapeutics market will exhibit an appreciable growth rate between 2023 and 2032. The increasing prevalence of chronic diseases, such as cancer, diabetes, and cardiovascular disorders, has created a significant need for effective treatment options. Rising healthcare expenditures, expanding middle-class population, and improving healthcare infrastructure have further contributed to the increasing demand. Besides, advancements in R&D capabilities in countries like China, Japan, and South Korea have fostered innovation, and the development of peptide-based therapies will drive market growth in the region.